The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
Open accessAbstract
Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from self or donors have their own advantages and disadvantages in their medical practice. Therapeutic benefits of using autologous vs. allogeneic MSCs are inconclusive. Transplanted MSCs within the body interact with their physical microenvironment or niche, physiologically or pathologically, and such cells in a newly established tissue microenvironment may be impacted by the pathological harmful environmental factors to alter their unique biological behaviors. Meanwhile, a temporary microenvironment/niche may be also altered by the resident or niche-surrounding MSCs. Therefore, the functional plasticity and heterogeneity of MSCs caused by different donors and subpopulations of MSCs may result in potential uncertainty in their safe and efficacious medical practice. Acknowledging a connection between MSCs’ biology and their existing microenvironment, donor-controlled clinical practice for the long-term therapeutic benefit is suggested to further consider minimizing MSCs potential harm for MSC-based individual therapies. In this review, we summarize the advantages and disadvantages of autologous vs. allogeneic MSCs in their therapeutic applications. Among other issues, we highlight the importance of better understanding of the various microenvironments that may affect the properties of niche-surrounding MSCs and discuss the clinical applications of MSCs within different contexts for treatment of different diseases including cardiomyopathy, lupus and lupus nephritis, diabetes and diabetic complications, bone and cartilage repair, cancer and tissue fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D. F., et al. (2016) · JAMA · doi:10.1001/jama.2016.0291 · Cited by 5,766
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
Acute respiratory distress syndrome
Thompson, B. T., Chambers, R. C., & Liu, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608077 · Cited by 1,807
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Dysregulation of bone homeostasis has been linked to age-related bone loss, especially in postmenopausal women [133, 134, 136], potentially leading to osteoporosis.”
BackgroundPerivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis
Kramann, R., Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., Henderson, J. M., Ebert, B. L., & Humphreys, B. D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.11.004 · Cited by 922 · cited 1×
“On the other hand, MSCs exist in the perivascular niche microenvironment [10] and the perivascular MSC-like cells are involved in tissue fibrosis, such as renal and heart fibrosis [121].”
Viswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Leblanc, K., Martin, I., Nolta, J., Phinney, D. G., & Sensebe, L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.08.002 · Cited by 839
Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., Baan, C. C., Dahlke, M. H., & Hoogduijn, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00297 · Cited by 804 · cited 1×
“Pulmonary passage seems to be a major obstacle for intravenous MSCs delivery for regenerative tissue therapy in preclinical studies [30, 31].”
Backgroundde Witte, S. F. H., Luk, F., Sierra Parraga, J. M., Gargesha, M., Merino, A., Korevaar, S. S., Shankar, A. S., O'Flynn, L., Elliman, S. J., Roy, D., et al. (2018) · Stem Cells · doi:10.1002/stem.2779 · Cited by 504
Melief, S. M., Zwaginga, J. J., Fibbe, W. E., & Roelofs, H. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0184 · Cited by 442
Cited by
Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review
Wu, K.-C., Chang, Y.-H., Ding, D.-C., & Lin, S.-Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312911 · Cited by 33
“This personalized approach enables for optimization of MSC source (whether autologous or allogeneic), dosage, and potential combination with other therapies, such as growth factors or drugs, ensuring that the therapy is best suited to the individual’s condition [197,198].”
Swain, H. N., Boyce, P. D., Bromet, B. A., Barozinksy, K., Hance, L., Shields, D., Olbricht, G. R., & Semon, J. A. (2024) · Biochimie · doi:10.1016/j.biochi.2024.04.009 · Cited by 13
Controversies regarding transplantation of mesenchymal stem cells
Velikova, T., Dekova, T., & Miteva, D. G. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90554 · Cited by 12
Future prospects in the tissue engineering of heart valves: a focus on the role of stem cells
Albert, B. J., & Butcher, J. T. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2214313 · Cited by 8
Metadata
- Authors
- Li, C., Zhao, H., Cheng, L., & Wang, B.
- Venue
- Cell & Bioscience
- Published
- 2021-11-02
- Volume
- 11
- Issue
- 1
- Pages
- 187-187
- ISSN
- 2045-3701 (ISSN-L)
- OpenAlex
- W3209651518
- Cited by
- 186
- References
- 17
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. https://app.cochat.ai/papers/10.1186/s13578-021-00698-y
- The paper
- Li, C., Zhao, H., Cheng, L., & Wang, B. (2021). Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell & Bioscience. https://doi.org/10.1186/s13578-021-00698-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.